Kevin R.  Sayer net worth and biography

Kevin Sayer Biography and Net Worth

CEO of DexCom

Kevin Sayer is the president, chairman, and CEO of Dexcom, a company that develops, manufactures, and distributes continuous glucose monitoring systems.

Sayer joined Dexcom as its president and chief operating officer in 2011, and he became CEO in 2015. In his various roles, he has directed research and development, manufacturing, regulatory, clinical, finance, marketing, and sales functions.

He has played a leading role in developing new technologies in the United States and Europe, including the Dexcom G5 Mobile CGM System and the Dexcom G4 PLATINUM System with Share, among others.

Before joining Dexcom, Sayer was the chief financial officer for medical technology company, Biosensors International. He has also served as an independent healthcare and medical technology industry consultant, as the executive vice president and CFO for Specialty Laboratories, and as the CFO of MiniMed from 1994 until 2001, when it was acquired by Medtronic. 

Sayer was recognized on Forbes’ “Innovative Leaders” list in 2019.

He earned both his B.S. and M.S. in accounting and information systems at Brigham Young University.

What is Kevin R. Sayer's net worth?

The estimated net worth of Kevin R. Sayer is at least $33.11 million as of April 8th, 2024. Mr. Sayer owns 283,893 shares of DexCom stock worth more than $33,113,280 as of June 19th. This net worth estimate does not reflect any other investments that Mr. Sayer may own. Additionally, Mr. Sayer receives an annual salary of $3,230,000.00 as CEO at DexCom. Learn More about Kevin R. Sayer's net worth.

How old is Kevin R. Sayer?

Mr. Sayer is currently 66 years old. There are 7 older executives and no younger executives at DexCom. Learn More on Kevin R. Sayer's age.

What is Kevin R. Sayer's salary?

As the CEO of DexCom, Inc., Mr. Sayer earns $3,230,000.00 per year. Learn More on Kevin R. Sayer's salary.

How do I contact Kevin R. Sayer?

The corporate mailing address for Mr. Sayer and other DexCom executives is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. DexCom can also be reached via phone at (858) 200-0200 and via email at [email protected]. Learn More on Kevin R. Sayer's contact information.

Has Kevin R. Sayer been buying or selling shares of DexCom?

Kevin R. Sayer has not been actively trading shares of DexCom within the last three months. Learn More on Kevin R. Sayer's trading history.

Who are DexCom's active insiders?

DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (CEO), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.

Are insiders buying or selling shares of DexCom?

During the last twelve months, insiders at the medical device company sold shares 39 times. They sold a total of 265,317 shares worth more than $34,660,713.42. The most recent insider tranaction occured on June, 14th when Director Bridgette P Heller sold 1,000 shares worth more than $113,550.00. Insiders at DexCom own 0.3% of the company. Learn More about insider trades at DexCom.

Information on this page was last updated on 6/14/2024.

Kevin R. Sayer Insider Trading History at DexCom

See Full Table

Kevin R. Sayer Buying and Selling Activity at DexCom

This chart shows Kevin R. Sayer's buying and selling at DexCom by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

DexCom Company Overview

DexCom logo
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $116.64
Low: $116.13
High: $117.49

50 Day Range

MA: $126.16
Low: $113.81
High: $139.62

2 Week Range

Now: $116.64
Low: $74.75
High: $142.00

Volume

2,192,895 shs

Average Volume

2,732,992 shs

Market Capitalization

$46.39 billion

P/E Ratio

75.25

Dividend Yield

N/A

Beta

1.22